VLCD & Adjuvant Exercise Effect in Overweight Diabetic Men
Launched by UNIVERSITY OF NOTTINGHAM · Jun 30, 2021
Trial Information
Current as of June 19, 2025
Completed
Keywords
ClinConnect Summary
Very low calorie diet (VLCD) is increasingly being utilized to improve cardio-metabolic outcomes in overweight/obese individuals with type 2 diabetes mellitus (T2DM), but concerns regarding its association with skeletal muscle mass losses persist, especially in middle-aged/older individuals, who are already at risk of accelerated sarcopenia. This is particularly relevant in people at risk of developing diabetes due to the rising incidence and prevalence of diabetes among older patients as well as accelerated sarcopenia in diabetes compared with non-diabetes. Given that low skeletal muscle m...
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Patients must be able to provide informed consent.
- • Adult patients between the age of 30-65 years
- • A body mass index (BMI) of between 27-50
- • Confirmed Type 2 Diabetes Mellitus (T2DM)
- Exclusion Criteria:
- • contrast (Sonovue) sensitivity,
- • known renal, musculoskeletal, neurological, bowel, cardiovascular, respiratory or cerebrovascular disease,
- • or current/recent formal exercise regime participation (within two years).
- • Prospective volunteers with a weight exceeding 120kg are ineligible to participate due to the weight restriction present in the DEXA machine.
About University Of Nottingham
The University of Nottingham is a leading research institution renowned for its commitment to advancing healthcare through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university harnesses cutting-edge research and expert faculty to address pressing medical challenges. Through its dedicated clinical trials unit, the University of Nottingham conducts rigorous studies aimed at improving patient outcomes and contributing to the global body of medical knowledge. The institution prioritizes ethical practices and participant safety, ensuring that all trials are designed to uphold the highest standards of scientific integrity and regulatory compliance.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Derby, Derbyshire, United Kingdom
Patients applied
Trial Officials
Iskandar Idris, BMBS FRCP DM
Principal Investigator
University of Nottingham
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials